Mixed Stocks: Oi SA (ADR)(NYSE:OIBR), StemCells Inc(NASDAQ:STEM), Autodesk, Inc.(NASDAQ:ADSK), Opko Health Inc.(NYSE:OPK)
Oi SA (ADR)(NYSE:OIBR) shares increased 12.70% to $2.13. Oi SA, formerly Brasil Telecom SA, is a Brazil-based holding company engaged in the telecommunication sector. The Company is primarily involved in the provision of fixed telephony services in Brazilian states of Acre, Rondonia, Mato Grosso, Mato Grosso do Sul, Tocantins, Goias, Parana, Santa Catarina and Rio Grande do Sul. Additionally, it offers a range of integrated telecommunication services, including mobile telecommunication services, data transmission and Internet service provider (ISP) services, among others.
Can Traders Buy OIBR After The Sharp Rise? Get Free Trend Analysis Here
StemCells Inc(NASDAQ:STEM) stock fell 14.28% to $1.44. StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development.
Is STEM A Strong At The CMP? Get Advantage Of Our Free Trend Analysis Here
Autodesk, Inc.(NASDAQ:ADSK) shares increased 3.51% to $41.91. Autodesk, Inc. (Autodesk) is a design software and services company. The Company operates in four operating segments: Platform Solutions and Emerging Business (PSEB), Architecture, Engineering and Construction (AEC), Manufacturing (MFG) and Media and Entertainment (M&E). The Company serves customers in the architecture, engineering and construction; manufacturing, and digital media and entertainment industries.
Is ADSK A Good Buy After The Recent Price Movement? Find Out Here
Opko Health Inc.(NYSE:OPK) stock gained 3.17% to $9.43. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions.
Is OPK A Strong At The CMP? Get Advantage Of Our Free Trend Analysis Here